The Era of N-Nitrosamines in the Pharmaceutical Industry – A Comprehensive Toxicological Perspective
- Rim Kaidi
- 2 days ago
- 4 min read
The unexpected appearance of N-nitrosamine impurities in medicines marked a major regulatory turning point. These compounds, already known to occur in the environment and food, compelled the global pharmaceutical industry to re-evaluate its manufacturing processes. In response, an unprecedented level of international coordination emerged among major regulatory agencies, including the FDA (United States), EMA (Europe), Anvisa (Brazil), and Health Canada, aiming to assess the extent of the issue and establish mitigation strategies. This event had a profound impact on the reassessment of manufacturing processes, enforcing increased vigilance and stricter controls at all stages of pharmaceutical production—from raw materials to finished products.
Toxicological Profile of N-Nitrosamines
Structure and Mechanism of Action
N-nitrosamines are characterized by a nitroso (-N=O) functional group bound to an amine (>NR₂). Their toxicity relies on a crucial bioactivation mechanism that begins with α-hydroxylation, primarily catalyzed by cytochrome P450 (CYP 450) enzymes. This step leads to the formation of unstable intermediates that subsequently generate reactive diazonium ions. These ions are highly electrophilic and can interact with DNA, causing irreversible genetic damage.
Mutagenic and Carcinogenic Properties
Due to their ability to alter DNA, N-nitrosamines are classified as mutagenic and genotoxic agents. Their properties also make them potent carcinogens. Extensive studies have shown that 82% of 228 tested nitrosamines were carcinogenic in vivo, underlining their hazardous nature. This high prevalence of carcinogenicity justifies the stringent regulatory measures implemented and the need to minimize their presence in pharmaceutical products.
The 2018 Crisis and Its Expansion
The N-nitrosamine crisis emerged in 2018, following the unexpected detection of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) in sartan drugs—commonly used for the treatment of hypertension and heart failure. This initial discovery quickly led to a broader investigation, revealing a more systemic issue. Contamination was subsequently identified in other widely prescribed medicines, including ranitidine (an H2 receptor antagonist), nizatidine (another antiulcer drug), and metformin (used to treat type 2 diabetes). The detection of these impurities resulted in large-scale product recalls worldwide, exposing the systemic nature of the problem and highlighting the need for a comprehensive reassessment of manufacturing and quality control processes within the pharmaceutical industry
Sources of N-Nitrosamine Contamination
Contamination of pharmaceuticals with N-nitrosamines can arise from multiple sources and complex mechanisms throughout the drug lifecycle. Understanding these origins is essential to prevent and mitigate their formation:
Formation during synthesis: Reaction between nitrites and secondary or tertiary amines (or their precursors) under acidic or high-temperature conditions. Reagents or intermediates may themselves be contaminated.
Contaminated solvents: Certain solvents such as Dimethylformamide (DMF) or N-Methyl-2-pyrrolidone (NMP) may degrade into amines or nitrites, leading to N-nitrosamine formation.
Recycled materials: Use of recycled solvents or reagents, if insufficiently purified, can introduce N-nitrosamines or their precursors.
Azide degradation: Azides used in specific syntheses may degrade in the presence of nitrites to form N-nitrosamines.
Excipients: Some excipients may contain tertiary amines (e.g., crospovidone, povidone) or be contaminated with nitrites, promoting in situ formation of N-nitrosamines in the finished product.
Active substance degradation: The active ingredient itself can degrade to generate amines or other precursors of N-nitrosamines.
Packaging materials: Primary packaging materials (e.g., certain plastic films or labels) may release amines or nitrites that react with the drug product.
Storage conditions: Elevated temperature and humidity during storage can accelerate component degradation and N-nitrosamine formation over time.
Regulatory Framework and Mitigation Strategies
Given the complexity and scale of the N-nitrosamine issue, regulatory agencies have established a structured three-step approach for the pharmaceutical industry:
Risk Assessment: The first step involves identifying potential risks of N-nitrosamine formation or contamination across the entire product portfolio. This requires a detailed analysis of synthesis pathways, raw materials, excipients, solvents, and manufacturing and storage conditions. Manufacturers must demonstrate that they have thoroughly evaluated and characterized these risks.
Confirmatory Testing: Following risk assessment, robust analytical testing is required to confirm the presence or absence of N-nitrosamines. High-sensitivity methods, such as liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), are preferred for their precision and ability to detect trace levels of these impurities.
Control and Mitigation: If N-nitrosamines are detected, or a significant risk is identified, control and mitigation strategies must be implemented. These may include modifications to synthesis routes, use of alternative raw materials, optimization of storage conditions, or the establishment of strict impurity limits. Dedicated working groups, such as the NISG (Nitrosamine Impurities Steering Group) and the NITWG (Nitrosamine Impurities Working Group), have been created to coordinate actions and share best practices globally.
Acceptable Intakes of N-Nitrosamines
To protect public health, regulatory authorities have defined Acceptable Intake (AI) limits for N-nitrosamines. The underlying principle is to ensure that the additional lifetime cancer risk remains below 1 in 100,000. Specific AI limits have been established for the most common N-nitrosamines:
NDMA (N-nitrosodimethylamine): 96 ng/day
NDEA (N-nitrosodiethylamine): 26.5 ng/day
For newly identified nitrosamines lacking compound-specific toxicological data, the Carcinogenic Potency Categorization Approach (CPCA) is applied. This approach classifies nitrosamines into carcinogenic potency categories (PC 1 to PC 5), each associated with corresponding AI limits. In addition, the Less-Than-Lifetime (LTL) concept allows temporary adjustment of exposure limits for shorter treatment durations, acknowledging that cumulative risk is lower over limited periods.
Need assistance ensuring regulatory compliance for your pharmaceutical products?